

BLOOD MONITORING, REIMAGINED

Introducing Sight OLO®
brought to you by AASPIRE

Fast, convenient, and
accurate blood monitoring
at the point of care



AA-Pharma is proud to partner with Sight Diagnostics®
to exclusively bring OLO to your patients on AA-Clozapine.

Intended for audiences in Canada only.

AA-Clozapine (clozapine) is indicated in the management of symptoms of treatment-resistant schizophrenia.¹



Reliable blood monitoring at your fingertips



OLO is licenced in Canada for performing CBC tests at the point of care.*³

OLO is a high-performance CBC analyzer. It delivers lab-grade results in minutes from 2 drops of blood obtained from 1 finger prick sample.²

Connectivity to LIS or middleware or directly to EHR/EMR enables seamless and secure integration of information to:




AASPIRE



The patient's electronic record

* Sight OLO is licensed by Health Canada as a Class III device (Licence No.: 106263).

CBC, complete blood count; EHR, electronic health record; EMR, electronic medical record; LIS, laboratory information system.



With OLO, routine bloodwork is simple and convenient, so you and your patients on AA-Clozapine have one less thing to worry about.

Just 1 finger prick and 2 drops of blood

OLO simplifies required blood monitoring with:



Point-of-care use

- On-site blood monitoring means real-time clinical decisions, with less hassle for your patients



Direct-from-finger prick testing

- Quick and less invasive than venipuncture²
- Removes one of the most common barriers to clozapine therapy



Just 2 drops of blood (27 µL)²

- Requires only 5% of the minimum blood volume needed for traditional lab-based testing methods²



Rapid results

- Actionable results are ready in minutes, enabling you to make faster treatment decisions for optimal patient care

Simple to set up and operate



OLO comes factory-calibrated for quick set-up and requires no routine maintenance or manual quality control (QC). With step-by-step onscreen guidance, it is designed to be easy for anyone to use.*2



Easy to install²

- Initial installation of OLO will be performed by our team
- Factory-calibrated for quick set-up



Easy to use^{2,4}

- Minimal training required
- Step-by-step touchscreen instructions
- Internal failsafe system ensures integrity of results



Easy to maintain²

- No maintenance or manual calibration for users
- No reagent management
- Remote support and servicing to reduce unnecessary downtime

* The device is intended to be operated by users trained on the use of the Sight OLO.

Better patient experience, better patient care in 3 easy steps²

1

Collect finger prick sample

Add 2 drops of capillary blood to the OLO single-use cartridge. The sample preparation process takes less than a minute.



2

Analyze with OLO

Insert the cartridge into OLO and wait for the machine-vision scanning to be performed.



3

View results

Full results are ready in minutes via touchscreen interface, printout, or email. View the results and transfer data to AASPIRE, The AA-Clozapine Patient Care Network, and your patient's electronic record.



Works for patients

Testing is less painful, non-invasive, and convenient, reducing the impact of required blood monitoring on your patient's quality of life.



Works for you

Reliable, real-time results empower you to make quick and informed treatment decisions.

Proven lab-grade results without the lab

OLO combines cutting-edge digital microscopy and artificial intelligence algorithms to deliver no-compromise CBC results.²

Comprehensive

OLO generates the full breadth of CBC test results:²



19 measured parameters⁴

- Performs a robust hematological analysis to support clinical decision-making



5-part differential⁴

- Reports the differential count (including ANC) required to initiate or continue treatment with AA-Clozapine¹



Sophisticated flagging capabilities⁴

- Detects and flags results that may be affected by abnormal cell morphology or other interferences



Extensive reportable and display range²

- Quantifies and reports CBC results across a wide range that covers the ANC values relevant to patients on AA-Clozapine¹


CBC parameters ⁴	
RBC	Red Blood Cell Count
HGB	Hemoglobin
HCT	Hematocrit
MCV	Mean Corpuscular Volume
MCH	Mean Corpuscular Hemoglobin
MCHC	Mean Corpuscular Hemoglobin Concentration
RDW	Red Blood Cell Distribution Width
PLT	Platelet Count
NEUT%/#	Neutrophil Percent and Count
LYMPH%/#	Lymphocyte Percent and Count
MONO%/#	Monocyte Percent and Count
EO%/#	Eosinophil Percent and Count
BASO%/#	Basophil Percent and Count

ANC, absolute neutrophil count; CBC, complete blood count;

Accurate

OLO provides CBC results that match best-in-class laboratory equipment. The Health Canada approval of OLO is based on substantially equivalent data comparing OLO to Sysmex XNTM.^{*2}

Neutrophils



Based on data from comparison studies performed at 3 US sites to evaluate OLO vs. a lab reference device (Sysmex XNTM).

For full indications for use and safety information, please refer to the Quality and Compliance page at <https://www.sightdx.com/quality-and-compliance>.

* All other trademarks are the property of their respective owners.

CBC, complete blood count; NEUT, neutrophil; WBC, white blood cell.

SIGHT OLO BROUGHT TO YOU BY AASPIRE. IT JUST WORKS.



References:

1. AA-Clozapine Product Monograph, AA Pharma Inc., May 6, 2020.
2. Sight Diagnostics data on file.
3. Sight OLO. Health Canada Medical Device Licence 106263. Issued November 2, 2021.
4. Sight OLO-U1 Operator's Manual. Sight Diagnostics. April 2021.

Sight OLO is a registered trademark of Sight Diagnostics.
© 2021 Sight Diagnostics Ltd., All rights reserved.
AA Pharma Inc. All rights reserved.

